Published in Diabetes Care on March 28, 2008
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes (2012) 1.20
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Diabetes and risk of cancer. ISRN Oncol (2013) 1.06
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control (2012) 1.01
Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res (2009) 1.01
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep (2015) 0.98
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol Immunother (2012) 0.91
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol (2013) 0.89
Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care (2012) 0.88
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int (2015) 0.85
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab (2011) 0.83
Novel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget (2015) 0.79
Cancer biology in diabetes. J Diabetes Investig (2014) 0.79
Adiponectin fine-tuning of liver regeneration dynamics revealed through cellular network modelling. J Physiol (2015) 0.79
Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid (2012) 0.78
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife (2016) 0.78
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget (2016) 0.76
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
Obesity, Diabetes and Cancer: A Mechanistic Perspective. Int J Diabetol Vasc Dis Res (2015) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Thiazolidinediones. N Engl J Med (2004) 9.42
Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med (2007) 4.12
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med (2007) 2.76
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther (2006) 1.57
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer (2003) 1.31
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med (2007) 1.16
Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med (2008) 1.14
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut (2004) 1.12
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 1.10
Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors. J Thorac Oncol (2007) 0.96
Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer? Int J Mol Med (2006) 0.92
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 0.85
Metformin and glitazones: do they really help PCOS patients? J Fam Pract (2007) 0.82
Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc (2013) 3.59
Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med (2011) 2.53
Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol (2008) 2.52
Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc (2009) 2.28
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J (2002) 2.27
Role of early symptoms in assessment of syncope in elderly people: results from the Italian group for the study of syncope in the elderly. J Am Geriatr Soc (2008) 1.97
Diagnosis and characteristics of syncope in older patients referred to geriatric departments. J Am Geriatr Soc (2006) 1.95
Prognostic stratification of older persons based on simple administrative data: development and validation of the "Silver Code," to be used in emergency department triage. J Gerontol A Biol Sci Med Sci (2009) 1.85
Subtle neurological abnormalities as risk factors for cognitive and functional decline, cerebrovascular events, and mortality in older community-dwelling adults. Arch Intern Med (2008) 1.71
Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol (2006) 1.70
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol (2011) 1.60
Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.60
DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther (2011) 1.59
Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care (2011) 1.58
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Cardiovascular remodeling is greater in isolated systolic hypertension than in diastolic hypertension in older adults: the Insufficienza Cardiaca negli Anziani Residenti (ICARE) a Dicomano Study. J Am Coll Cardiol (2002) 1.56
Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med (2010) 1.54
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin (2011) 1.48
Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry. Intern Emerg Med (2008) 1.48
Usefulness and safety of shortened head-up tilt testing potentiated with sublingual glyceryl trinitrate in older patients with recurrent unexplained syncope. J Am Geriatr Soc (2002) 1.47
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev (2006) 1.47
The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med (2010) 1.46
Efficacy of physiotherapy interventions late after stroke: a meta-analysis. J Neurol Neurosurg Psychiatry (2010) 1.46
Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry (2013) 1.45
Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med (2004) 1.45
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf (2014) 1.44
The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study. J Am Coll Cardiol (2004) 1.44
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism (2008) 1.43
Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol (2011) 1.42
Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index? Fertil Steril (2013) 1.41
Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates. J Androl (2010) 1.41
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci (2013) 1.32
Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One (2012) 1.32
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Early and late outcome of treated patients referred for syncope to emergency department: the EGSYS 2 follow-up study. Eur Heart J (2010) 1.31
Screening of older community-dwelling people at risk for death and hospitalization: the Assistenza Socio-Sanitaria in Italia project. J Am Geriatr Soc (2007) 1.31
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol (2009) 1.30
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2008) 1.30
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol (2009) 1.25
Reduced cardiocirculatory complications with unrestrictive visiting policy in an intensive care unit: results from a pilot, randomized trial. Circulation (2006) 1.24
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2007) 1.23
Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res (2011) 1.22
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Predictive validity of measures of comorbidity in older community dwellers: the Insufficienza Cardiaca negli Anziani Residenti a Dicomano Study. J Am Geriatr Soc (2006) 1.15
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care (2008) 1.14
Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab (2011) 1.14
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res (2011) 1.12
Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke (2007) 1.12
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care (2007) 1.12
Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev (2006) 1.11
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol (2013) 1.10
Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med (2014) 1.10
Diagnostic crossover and outcome predictors in eating disorders according to DSM-IV and DSM-V proposed criteria: a 6-year follow-up study. Psychosom Med (2011) 1.08
Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate (2012) 1.07
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res (2012) 1.06
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev (2011) 1.05
Impaired attention predicts motor performance decline in older community-dwellers with normal baseline mobility: results from the Italian Longitudinal Study on Aging (ILSA). J Gerontol A Biol Sci Med Sci (2007) 1.05
Physical exercise and comorbidity. Results from the Fitness and Arthritis in Seniors Trial (FAST). Aging Clin Exp Res (2006) 1.02
The metabolic syndrome in treatment-seeking obese persons. Metabolism (2004) 1.00
Finger sepsis in two poorly controlled diabetic patients with reuse of lancets. Diabetes Care (2002) 0.99
Correlations between binge eating and emotional eating in a sample of overweight subjects. Appetite (2009) 0.99
Cystatin C reference values and aging. Clin Biochem (2006) 0.99
Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med (2009) 0.99
Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med (2008) 0.99
Fall prevention in the elderly. Clin Cases Miner Bone Metab (2013) 0.98
Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med (2007) 0.98
The association between varicocele, premature ejaculation and prostatitis symptoms: possible mechanisms. J Sex Med (2009) 0.98
Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol (2007) 0.97
Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med (2009) 0.97
Serum PSA as a predictor of testosterone deficiency. J Sex Med (2013) 0.96
Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clin Exp Res (2007) 0.96
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol (2009) 0.95
Epidemiology of suboptimal prescribing in older, community dwellers: a two-wave, population-based survey in Dicomano, Italy. Drugs Aging (2009) 0.95
Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int J Cancer (2013) 0.94
Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Lab Invest (2008) 0.94
Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes (2004) 0.94
PET positivity with bone marrow biopsy revealing sarcoidosis in a patient in whom bone marrow metastases had been suspected. Br J Haematol (2008) 0.93